Targeting the ATX-LPA-LPA1-6 pathway holds therapeutic potential, as this signaling axis may promote the development of metabolic disorders through multiple mechanisms involving inflammation, fibrosis, and impaired mitochondrial function and PPARγ activation. The gene discussed is ENPP2; the disease is metabolic disease.